FrancophonIA/ELRC3.0 huggingface dataset:
English: After the first dose, Prevenar 13 elicited antibody levels, measured by both IgG GMCs and OPA GMTs that were statistically significantly higher when compared to levels prior to vaccination.
Estonian: Pärast esimest annust kutsus Prevenar 13 esile antikehade taseme, mis olid nii IgG geomeetriliste keskmiste kontsentratsioonide kui ka OPA geomeetriliste keskmiste tiitrite järgi mõõdetuna vaktsineerimiseelse tasemega võrreldes statistiliselt tunduvalt kõrgem.
English: However, in infants and children there have been reports of overdose with Prevenar 13 defined as subsequent doses administered closer than recommended to the previous dose.
Estonian: Siiski on Prevenar 13 üleannustamist esinenud imikutel ja lastel järgnevate annuste soovitatud intervallist varasema manustamisena.
English: Overdose with Prevenar 13 is unlikely due to its presentation as a single dose vial.
Estonian: Kuna Prevenar 13 turustatakse üheannuselistes viaalides, on üleannustamine ebatõenäoline.
English: • Collapse or shock-like state (hypotonic-hyporesponsive episode)
Estonian: • kublad (nõgestõbi või nõgestõvetaoline lööve)
English: In addition, OPA GMTs between subjects receiving Prevenar 13 with or without 2-PE were compared.
Estonian: Peale selle võrreldi Prevenar 13 (kas 2-PE-ga või ilma) saanud uuringus osalejatel funktsionaalsete antikehade (OPA) tiitrite geomeetrilisi keskmisi.
English: Common side effects (these may occur with up to 1 in 10 doses of the vaccine) are:
Estonian: Sagedased kõrvaltoimed (neid võib esineda kuni 1 vaktsiiniannuse puhul 10st) on järgmised:
English: Teл: +359 2 970 4333
Estonian: Tel: + 421 2 3355 5500
English: Nausea
Estonian: lööve
English: Table 9: OPA GMTs in pneumococcal polysaccharide vaccinated adults aged ≥ 70 years given either Prevenar 13 or 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Estonian: OPA tiitrite geomeetrilised keskmised pärast Prevenar 13 või 23-valentse pneumokokkidevastase polüsahhariidvaktsiini manustamist vähemalt 70-aastastel täiskasvanutel, keda oli varem vaktsineeritud pneumokokkidevastase polüsahhariidvaktsiiniga a,b,c
English: • Decreased appetite; headaches; diarrhoea; vomiting (for those 18 to 49 years of age) • Chills; tiredness; rash; pain, redness, swelling hardness or tenderness at the vaccination-site,
Estonian: • isu vähenemine, peavalu, kõhulahtisus; oksendamine (18...49-aastastel)
English: Pneumococcal polysaccharide serotype 4
Estonian: 2,2 µg pneumokoki serotüübi 4
English: Sodium chloride, succinic acid, polysorbate 80 and water for injections
Estonian: Naatriumkloriid, merevaikhape, polüsorbaat 80 ja süstevesi.
English: 50-59 Years N=350-384
Estonian: aastased N=359…404
English: Pneumococcal polysaccharide serotype 3
Estonian: 2,2 µg pneumokoki serotüübi 3
English: USA (2000)
Estonian: Ameerika Ühendriigid
English: In infants and children there have been reports of overdose with Prevenar 13 defined as subsequent doses administered closer than recommended to the previous dose.
Estonian: Prevenar 13 üleannustamist on esinenud imikutel ja lastel järgnevate annuste soovitatud intervallist varasema manustamisena.
English: Slovenská republika Pfizer Luxembourg SARL, organizačná zložka Tel: + 421 2 3355 5500
Estonian: Пфайзер Люксембург САРЛ, Клон Бьлгария Teл: +359 2 970 4333
English: Single Dose Vial Label
Estonian: Ühennuselise viaali silt
English: What is in this leaflet
Estonian: näiteks kaenla all
English: Adults 50-59 years not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Estonian: 50…59-aastased täiskasvanud, keda ei olnud varem 23-valentse pneumokokkidevastase polüsahhariidvaktsiiniga vaktsineeritud 60…64-aastased täiskasvanud, keda ei olnud varem 23-valentse pneumokokkidevastase polüsahhariidvaktsiiniga vaktsineeritud
English: Incidence rate reduction (95% CI)
Estonian: Vaktsiini efektiivsus % (95% CI) (ühepoolne p-väärtus)
English: Increased reporting rates of convulsions (with or without fever) and hypotonic hyporesponsive episode (HHE) were observed with concomitant administration of Prevenar 13 and Infanrix hexa (see section 4.8).
Estonian: Prevenar 13 ja Infanrix hexa kooskasutamisel on täheldatud krampide (koos palavikuga või ilma) ja hüpotoonilise hüporeaktiivse episoodi esinemissageduste suurenemist (vt lõik
English: 9V
Estonian: 19F
English: Cases
Estonian: ABIAINED
English: Booster responses following two-dose and three-dose primary infant series
Estonian: Revaktsineerimise immuunvastused imikutel pärast esmast kahe- ja kolmeannuselist vaktsineerimist
English: Prevenar 13 suspension for injection in single dose vial IM
Estonian: Prevenar 13 süstesuspensioon üheannuselises viaalis i.m.
English: Relative to 60-64 Years
Estonian: 18…49-aastased võrdluses 60…64-aastastega
English: Table 6: Vaccine efficacy (VE) against clinical CAP
Estonian: Vaktsiini efektiivsus kliinilise olmetekkelise kopsupõletiku vastu Episoodid
English: For Prevenar 13 recipients, the proportion of responders with an OPA titre  1:8 was at least 87 % following the infant series, and at least 93% following the booster dose.
Estonian: Prevenar 13-ga vaktsineeritutel tekkis pärast imikuea vaktsineerimist immuunvastus OPA tiitriga ≥ 1:8 vähemalt 87%-l ning pärast revaktsineerimisannust vähemalt 93%-l. Serotüüpide 1, 3 ja 5 puhul olid OPA tiitrite geomeetrilised keskmised madalamad kui ülejäänud täiendavate serotüüpide puhul; selle tulemuse kliiniline asjakohasus ei ole teada.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Humalog on 30 April 1996.
Estonian: Euroopa Komisjon andis Humalogi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 30. aprillil 1996.
English: Humalog Mix is a mixture of these two formulations.
Estonian: Humalog Mix on nende kahe vormi segu.
English: What measures are being taken to ensure the safe and effective use of Humalog?
Estonian: Mis meetmed võetakse, et tagada Humalogi ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Humalog is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Humalogi võimalikult ohutu kasutamine.
English: The full EPAR for Humalog can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Humalogi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Humalog insulin lispro
Estonian: Humalog lisproinsuliin
English: Other information about Humalog
Estonian: Muu teave Humalogi kohta
English: Studies also looked at the use of Humalog in 542 patients aged between two and 19 years, and the use of Humalog in combination with sulphonylureas.
Estonian: Uuriti ka Humalogi kasutamist 542 patsiendil vanuses 2-19 aastat ja Humalogi kasutamist koos sulfonüüluurearavimitega.
English: The Committee recommended that Humalog be given marketing authorisation.
Estonian: Komitee soovitas anda Humalogi müügiloa.
English: • Humalog Basal: insulin lispro protamine suspension;
Estonian: • Humalog Basal: lisproinsuliini protamiinisuspensioon;
English: • Humalog: insulin lispro solution, available in a standard or a higher strength (100 or 200 units/ml);
Estonian: • Humalog: lisproinsuliini lahus, turustatakse standardse või suure tugevusega (100 või 200 ühikut/ml);
English: Humalog doses might need to be adjusted when given with other medicines that may have an effect on blood glucose levels.
Estonian: Humalogi annust võib olla vaja kohandada, kui seda võetakse koos muu ravimiga, mis võib mõjutada vere glükoosisisaldust.
English: Humalog and Humalog Mix are normally given shortly before a meal, but they can be given just after a meal if necessary.
Estonian: Humalogi ja Humalog Mixi manustatakse tavaliselt vahetult enne sööki või vajaduse korral vahetult pärast sööki.
English: For more information about treatment with Humalog, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Humalogiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Humalog.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Humalog may cause hypoglycaemia (low blood glucose levels) and must not be given to patients whose blood glucose is already low.
Estonian: Humalog võib põhjustada hüpoglükeemiat (vere väike glükoosisisaldus) ja seda ei tohi võtta patsiendid, kelle vere glükoosisisaldus on juba väike.
English: Diabetes is a disease in which the body does not produce enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Estonian: II tüüpi diabeet on haigus, mille korral organismis ei teki vere glükoosisisalduse reguleerimiseks piisavalt insuliini või organism ei suuda insuliini efektiivselt kasutada.
English: What is the risk associated with Humalog?
Estonian: Mis riskid Humalogiga kaasnevad?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Humalog, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Humalogi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled, and ‘fasting' blood glucose levels (measured when the patient had not eaten for at least eight hours).
Estonian: Uuringutes mõõdeti teatud aine, glükohemoglobiini (HbA1c) sisaldust veres, mis näitab, kui hästi reguleerib organism vere glükoosisisaldust, ja vere glükoosisisaldust tühja kõhu korral (kui söömisest oli möödunud vähemalt kaheksa tundi).
English: What is Humalog?
Estonian: Mis on Humalog?
English: In addition, the company that makes Humalog has provided information to patients and healthcare professionals to remind them that there are two strengths of Humalog and to advise them on how to use them safely to avoid medication errors.
Estonian: Lisaks annab Humalogi tootja patsientidele ja tervishoiutöötajatele teabematerjalid, milles neile meenutatakse ravivigade ennetamiseks, et Humalogi turustatakse kahes tugevuses, ning selgitatakse nende ohutut kasutamist.
English: Humalog is a replacement insulin which is very similar to the insulin made by the body.
Estonian: Humalog on asendusinsuliin, mis on väga sarnane organismis tekkiva insuliiniga.
English: Humalog was originally studied in eight clinical trials including 2951 patients with type 1 diabetes (when the body cannot produce insulin) or type 2 diabetes (when the body is unable to use insulin effectively).
Estonian: Humalogiga on tehtud kaheksa kliinilist uuringut, milles osales kokku 2951 patsienti, sealhulgas I tüüpi diabeediga patsiendid, kelle kõhunääre ei suuda toota insuliini, ja II tüüpi diabeediga patsiendid, kelle organism ei ole suuda insuliini tõhusalt kasutada.
English: The effectiveness of Humalog was compared with that of Humulin R (a soluble recombinant DNA human insulin), when added to long-acting insulins given once or twice a day.
Estonian: Humalogi efektiivsust võrreldi ravimi Humulin R efektiivsusega (lahustuv rekombinant-DNA-iniminsuliin): mõlemat ravimit lisati pika toimeajaga insuliinidele, mida manustati üks või kaks korda ööpäevas.
English: For the full list of all side effects and restrictions with Humalog, see the package leaflet.
Estonian: Humalogi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: This is a summary of the European public assessment report (EPAR) for Humalog.
Estonian: See on ravimi Humalog Euroopa avaliku hindamisaruande kokkuvõte.
English: Humalog Mix, Humalog Basal and Humalog 200 units/ml should never be given into a vein.
Estonian: Humalog Mixi, Humalog Basalit ja Humalogi tugevusega 200 ühikut/ml ei tohi manustada veeni.
English: The Committee for Medicinal products for Human Use (CHMP) decided that Humalog's benefits are greater than its risks for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis, and for the initial stabilisation of diabetes mellitus.
Estonian: Inimravimite komitee otsustas, et Humalogi kasulikkus diabeediga ja glükoosi normaalse homeostaasi hoidmiseks ja diabeedi esialgseks stabiliseerimiseks insuliiniravi vajavate täiskasvanute ja laste ravis on suurem kui ravimiga kaasnevad riskid.
English: The Humalog range comprises fast-acting insulin solutions (Humalog), longer-acting insulin suspensions (Humalog Basal), and combinations of both in various proportions (Humalog Mix):
Estonian: Humalogi tootesari sisaldab kiiretoimelisi insuliinilahuseid (Humalog), pikatoimelisi insuliinisuspensioone (Humalog Basal) ja mõlemat tüüpi eri suhtes sisaldavaid kombinatsioone (Humalog Mix):
English: Patients can inject themselves with this medicine if they have been trained appropriately.
Estonian: Kui patsiendid on saanud asjakohase väljaõppe, tohivad nad Humalogi endale ise süstida.
English: The active substance in Humalog, insulin lispro, is produced by a method known as ‘recombinant DNA technology': it is made by bacteria into which a gene (DNA) has been introduced, which makes them able to produce insulin lispro.
Estonian: Humalogi toimeainet lisproinsuliini valmistatakse rekombinant-DNA-tehnika abil: seda toodavad bakterid, millele on lisatud lisproinsuliini teket võimaldav geen (DNA).
English: Humalog can be used with a longer-acting insulin or with sulphonylureas (a group of diabetes medicines that are taken by mouth).
Estonian: Humalogi tohib kasutada koos pika toimeajaga insuliiniga või sulfonüüluurearavimitega (teatud suukaudsed diabeediravimid).
English: What benefit has Humalog shown during the studies?
Estonian: Milles seisneb uuringute põhjal Humalogi kasulikkus?
English: What is Humalog used for?
Estonian: Milleks Humalogi kasutatakse?
English: Humalog 200 units/ml must only be injected under the skin, using the KwikPen device in which it is supplied.
Estonian: Humalogi tugevusega 200 ühikut/ml tohib manustada ainult nahaaluse süstena, kasutades KwikPen-pensüstalt, milles ravimit turustatakse.
English: Insulin lispro is available as Humalog in the soluble form, which acts more or less immediately after injection, and as Humalog Basal in the ‘protamine suspension' form, which is absorbed much more slowly so that it works for longer.
Estonian: Humalog sisaldab lisproinsuliini lahustuval kujul, mis toimib peaaegu kohe pärast süstimist; Humalog Basal sisaldab lisproinsuliini protamiinisuspensioonina, mis imendub tunduvalt aeglasemalt, nii et toime on pikaajalisem.
English: Humalog 100 units/ml may also be given by continuous infusion using an insulin pump or into a vein.
Estonian: Humalogi tugevusega 100 ühikut/ml tohib manustada ka veeni või pidevinfusioonina, kasutades insuliinipumpa.
English: How has Humalog been studied?
Estonian: Kuidas Humalogi uuriti?
English: How is Humalog used?
Estonian: Kuidas Humalogi kasutatakse?
English: Humalog is used to treat patients who have diabetes and need insulin to keep their blood glucose (sugar) level controlled, including patients whose diabetes has just been diagnosed.
Estonian: Humalogi kasutatakse diabeediga patsientide, sealhulgas äsja diagnoositud diabeediga patsientide raviks, kes vajavad vere glükoosisisalduse reguleerimiseks insuliini.
English: Humalog, Humalog Basal and Humalog Mix may be given by injection under the skin of the upper arm, thigh, buttock or abdomen (tummy).
Estonian: Humalogi, Humalog Basalit ja Humalog Mixi manustatakse nahaaluse süstena õlavarre, reie, tuhara või kõhu piirkonda.
English: Why has Humalog been approved?
Estonian: Miks Humalog heaks kiideti?
English: How does Humalog work?
Estonian: Kuidas Humalog toimib?
English: The medicine can only be obtained with a prescription.
Estonian: Humalog on retseptiravim.
English: Humalog and Humulin R had a similar effect on the control of diabetes, as measured by HbA1c and fasting glucose levels.
Estonian: Glükohemoglobiini sisalduse ja tühja kõhu korral mõõdetud glükoosisisalduse põhjal selgus, et Humalog ja Humulin R toime vere glükoosisisaldusele oli sarnane.
English: Humalog is a range of solutions and suspensions for injection that contain the active substance insulin lispro and are supplied in vials, cartridges and prefilled pens (Humalog KwikPen).
Estonian: Seda turustatakse viaalides, kolbampullides ja eeltäidetud pensüstaldes (Humalog KwikPen).
English: It is used in children and adolescents from 4 to 18 years of age.
Estonian: Seda kasutatakse lastel ja noorukitel vanuses 4-18.
English: What measures are being taken to ensure the safe and effective use of Verkazia?
Estonian: Mis meetmed võetakse, et tagada Verkazia ohutu ja efektiivne kasutamine?
English: Applying it directly to the eye reduces eye inflammation but limits its effects elsewhere in the body.
Estonian: Selle tilgutamine otse silma vähendab silmapõletikku, kuid piirab selle toimet mujal organismis.
English: What is Verkazia and what is it used for?
Estonian: Mis on Verkazia ja milleks seda kasutatakse?
English: Other information about Verkazia
Estonian: Muu teave Verkazia kohta
English: The European Medicines Agency therefore decided that Verkazia's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Seetõttu otsustas Euroopa Ravimiamet, et Verkazia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Verkazia ciclosporin
Estonian: Verkazia tsüklosporiin
English: In a main study involving 169 children and adolescents with severe VKC, 55% of patients treated with Verkazia achieved CFS improvements of 50% or more, without the need of other medications, after 4 months, compared with around 28% of patients receiving a dummy treatment.
Estonian: Põhiuuringus, milles osales 169 raske kevadkeratokonjunktiviidiga last ja noorukit, saavutasid 55% Verkaziaga ravitud patsientidest 4 kuu järel CFS-skoori vähemalt 50% paranemise, ilma et oleks vajanud muid ravimeid; platseebot (näiv ravim) saanud patsientide seas saavutas sama tulemuse umbes 28% patsientidest.
English: Some of the patients were treated for an additional 8 months; this extension study showed that the benefits of Verkazia were maintained with continued use for up to 12 months.
Estonian: Osal patsientidest pikendati ravi veel 8 kuu võrra; selles jätku-uuringus tõendati, et Verkazia ravitoime püsis pideval kasutamisel kuni 12 kuu jooksul.
English: Why is Verkazia approved?
Estonian: Miks Verkazia heaks kiideti?
English: Verkazia must not be used in patients with active or suspected infections in or around the eye.
Estonian: Verkaziat ei tohi kasutada patsiendid, kellel on silmas või silmaümbruses aktiivne infektsioon või kellel seda kahtlustatakse.
English: It is not intended to provide practical advice on how to use Verkazia.
Estonian: Hindamisaruandes ei anta Verkazia kasutamise praktilisi nõuandeid.
English: What are the risks associated with Verkazia?
Estonian: Mis riskid Verkaziaga kaasnevad?
English: Verkazia has been shown to be effective at improving the condition of the cornea and reducing the symptoms of the disease.
Estonian: Verkazia on osutunud efektiivseks sarvkesta seisundi parandamisel ja haigussümptomite vähendamisel.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Verkazia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Verkazia kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Side effects are mostly mild and disappear shortly after application of the medicine.
Estonian: Kõrvalnähud on enamasti kerged ja mööduvad peatselt pärast ravimi manustamist.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Verkazia have been included in the summary of product characteristics and the package leaflet.
Estonian: Verkazia ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: If symptoms persist after the end of the season, Verkazia can continue to be used at the recommended dose until symptoms are under control and at a reduced dose (1 drop twice a day) thereafter.
Estonian: Kui kevadkeratokonjunktiviidi sümptomid püsivad ka pärast hooaja lõppu, võib ravi jätkata soovitatavas annuses ning pärast sümptomite üle piisava kontrolli saavutamist annust vähendada (1 tilk 2 korda ööpäevas).
English: Verkazia contains the active substance ciclosporin.
Estonian: Verkazia sisaldab toimeainena tsüklosporiini.
English: The full EPAR for Verkazia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Verkazia kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The recommended dose is 1 drop 4 times a day in each affected eye, during VKC season.
Estonian: Soovitatav annus on 1 tilk kummassegi kahjustatud silma 4 korda ööpäevas kevadkeratokonjunktiviidi hooajal.
English: Verkazia is a medicine used to treat severe vernal keratoconjunctivitis (VKC), an allergic condition that affects the eye and mostly occurs seasonally, although in some patients symptoms can recur or persist all year round.
Estonian: Verkazia on ravim, mida kasutatakse raske kevadkeratokonjunktiviidi (allergiline silmahaigus, mis enamasti esineb kevaditi, kuigi osal patsientidest võib see korduda või püsida terve aasta) raviks.
English: How is Verkazia used?
Estonian: Kuidas Verkaziat kasutatakse?
English: These symptoms usually occur when the drops are being put in the eyes and go away shortly after.
Estonian: Need sümptomid esinevad enamasti ravimi tilgutamisel silmadesse ja mööduvad kiiresti.
English: Verkazia reduces damage to the cornea (layer in the front of the eye) in most patients with VKC as shown by improvements in ‘corneal fluorescence staining' (CFS) scores (a standard measure of corneal health).
Estonian: Verkazia vähendab enamikul kevadkeratokonjunktiviidiga patsientidel sarvkesta (silma eesosas paiknev kiht) kahjustusi, nagu näitab sarvkesta fluorestseiiniga värvimise (CFS) skoori (sarvkesta seisundit kajastav standardskoor) paranemine.
English: Because the number of patients with vernal keratoconjunctivitis is low, the disease is considered ‘rare', and Verkazia was designated an ‘orphan medicine' (a medicine used in rare diseases) on 6 April 2006.
Estonian: Et kevadkeratokonjunktiviidiga patsiente on vähe ja seda haigust esineb harva, nimetati Verkazia 6. aprillil 2006 harvikravimiks.
English: Verkazia is available as eye drops.
Estonian: Verkaziat turustatakse silmatilkadena.
English: For practical information about using Verkazia, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Verkazia kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Verkazia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Verkaziaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.